Trial Profile
A Phase II Study of Tetrathiomolybdate in Patients With Breast Cancer at Moderate to High Risk of Recurrence
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Tetrathiomolybdate (Primary)
- Indications Advanced breast cancer; Early breast cancer; Inflammatory breast cancer
- Focus Therapeutic Use
- 03 Jul 2023 Planned End Date changed from 1 Jun 2023 to 1 Jun 2025.
- 03 Jul 2023 Planned primary completion date changed from 1 Jun 2023 to 1 Jun 2025.
- 20 Apr 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.